Contemporary management of atrial fibrillation in patients with cancer—the 2025 European Heart Rhythm Association survey
Authors' conclusion
The survey revealed that, despite the lack of robust evidence specific to this patient cohort, contemporary treatment of AF in patients with active cancer or a history of cancer therapy generally follows guidelines developed for the broader AF population.
Study context
- Population
- Physicians managing atrial fibrillation (AF) in patients with active cancer or a history of cancer therapy
- Participants
- 380 physicians · 74 countries
- Exposure
- Active cancer vs History of cancer therapy
- Outcome
- Current clinical practices in diagnosis and management of AF in patients with active cancer or a history of cancer therapy
Methodological detailsphysician-based survey, 25-item questionnaire, electronic dissemination, Developed by EHRA with ESC Council of Cardio-Oncology and International Cardio-Oncology Society
- Physician-based survey
- 25-item questionnaire
- Electronic dissemination
- Developed by EHRA with ESC Council of Cardio-Oncology and International Cardio-Oncology Society
Main finding
As reported in the abstract
AF management practices
- Respondents: electrophysiologists
- 30%
- Respondents: general cardiologists
- 25%
- Respondents: cardio-oncologists
- 22%
- Active cancer 'definitely' or 'most probably' influenced AF decisions
- Nearly two-thirds
- History of cancer therapy 'definitely' or 'most probably' influenced AF decisions
- A little over 40%
- History of cancer therapy: rhythm control most common strategy
- 40%
Observational data: associations, not effects.
Original publication
Contemporary management of atrial fibrillation in patients with cancer—the 2025 European Heart Rhythm Association survey. Europace. Published 19 February 2026. doi:10.
Summarised from the published abstract; every number is checked against it